Companies /Healthcare
Stryker Corp
NYSE: SYK Medical Devices
$276.10
▲ $0.70 (+0.25%) today
Markets open · 10:03am ET

Stryker (SYK) Q4 2025 Earnings

Reported Jan 29, 2026, 4:11pm ET · SEC source
$4.47
Beat +1.59%
EPS · est. $4.40
$7.2B
Beat +0.98%
Revenue · est. $7.1B
+4.3%
Beating market
SYK vs S&P since report
6 quarters
Consecutive EPS beats

How Did SYK Stock React to Q4 2025 Earnings?

% change · around the report
−4%−2%0Jan 29Jan 30report 4:11pm ETearnings−0.3%−0.1%
−4%−2%0Jan 29Jan 30earnings−0.3%−0.1%
SYK −0.1%S&P 500 −0.3%
−4%−2%0Jan 29Jan 30report 4:11pm ETearnings−1.3%−0.1%
−4%−2%0Jan 29Jan 30earnings−1.3%−0.1%
SYK −0.1%NASDAQ −1.3%
−2%0+2%Jan 28Feb 6report 4:11pm ETearnings−0.5%−1.0%
−2%0+2%Jan 28Feb 6earnings−0.5%−1.0%
SYK −1.0%S&P 500 −0.5%
−6%−3%0+3%Jan 28Feb 6report 4:11pm ETearnings−3.2%−1.0%
−6%−3%0+3%Jan 28Feb 6earnings−3.2%−1.0%
SYK −1.0%NASDAQ −3.2%
+4.31%
Day of report
−0.38%
Next session
−3.05%
One week
+3.34%
30 days

S&P 500 over the same 30 days: −0.99%.

Did SYK Beat Earnings? Q4 2025 Results

Yes. Stryker reported Q4 2025 earnings of $4.47 a share on Jan 29, 2026, beating the $4.40 consensus estimate by 1.6%. Revenue was $7.2B against a $7.1B estimate.

Stryker closed out fiscal 2025 on a strong note, delivering a fourth-quarter beat on both the top and bottom lines as the medical device giant crossed a milestone $25 billion in annual revenue for the first time. Adjusted EPS of $4.47 edged past the $4.40 consensus estimate by 1.59%, while revenue of $7.17 billion topped expectations by 0.98% and grew 11.4% year-over-year, driven in large part by the MedSurg and Neurotechnology segment, which posted 17.5% reported growth to $4.56 billion, with Vascular sales surging 58.1% on the strength of the Inari Medical acquisition completed earlier in the year. Adjusted operating income margin expanded 100 basis points to 30.2%, marking the second straight year of at least that level of margin improvement. The company's limited market release of its Mako RPS handheld robotic system adds a promising new dimension to its orthopedic robotics portfolio heading into 2026, when management expects organic net sales growth of 8.0% to 9.5% and adjusted diluted EPS of $14.90 to $15.10.

Key Takeaways
  • Organic net sales growth of 11.0% in Q4 driven by 10.9% increased unit volume and 0.1% higher prices
  • MedSurg and Neurotechnology organic sales growth of 12.6% in Q4
  • Orthopaedics organic sales growth of 8.4% in Q4
  • Vascular segment Q4 sales surged 58.1% driven by the Inari Medical acquisition
  • Adjusted operating margin expanded 100 bps to 30.2% in Q4
  • Strong procedural volumes and capital product demand

“We had an outstanding finish to 2025, driving double-digit sales and adjusted earnings per share growth for the fourth quarter and full year while delivering adjusted operating margin expansion of at least 100 basis points for the second consecutive year.”

Stryker CEO, on the earnings call

What Was Stryker's Outlook in Q4 2025?

For 2026, Stryker expects organic net sales growth of 8.0% to 9.5% and adjusted net earnings per diluted share in the range of $14.90 to $15.10. Full-year sales guidance includes a modestly favorable pricing impact. Foreign exchange is expected to have a slightly positive impact on both sales and adjusted net earnings per diluted share should rates hold near year-to-date levels. The outlook is supported by momentum exiting 2025, healthy procedural volumes, and strong demand for capital products.

SYK YoY Financials

Q4 2025 vs Q4 2024 · SEC filings Q4 2024 Q4 2025
$0$2.0B$4.0B$6.0B$6.4B$7.2BRevenue$4.0B$4.6BGross Profit$1.7B$1.8BOperating Income$546.0M$849.0MNet Income
$0$2.0B$4.0B$6.0BRevenueGross ProfitOperating IncomeNet Income
SYK income statement, Q4 2025 versus Q4 2024
Metric Q4 2025 Q4 2024 Year over year
Revenue $7.2B $6.4B +11.4%
Gross Profit $4.6B $4.0B +16.0%
Operating Income $1.8B $1.7B +8.5%
Net Income $849.0M $546.0M +55.5%

SYK Revenue by Segment

MedSurg and Neurotechnology$4.6B+17.5%
Orthopaedics$2.6B+2.2%
Medical$1.3B+12.4%
Endoscopy$1.1B+13.8%
Trauma and Extremities$1.1B+9.1%
Instruments$925.0M+17.1%
Knees$749.0M+8.9%
Other Orthopaedics$267.0M+20.1%

SYK Revenue by Geography

United States$5.4B+11.7%
Rest of World$1.7B+10.6%

Figures from SEC filings and company reports. Not investment advice.